Resistant Hypertension in Chronic Kidney Disease

341

Recommended Reading

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treat-
   ment a scientific statement from the American Heart Association professional education
   Committee of the Council for high blood pressure research. Hypertension. 2008;51:1403.


2. Calhoun DA, White WB.  Effectiveness of the selective aldosterone blocker, eplerenone, in
   patients with resistant hypertension. J Am Soc Hypertens. 2008;2:462.


3. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary
   hypertension. Am J Med. 2012;125:14.


4. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Task Force Members,
   et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for
   the management of arterial hypertension of the European Society of Hypertension (ESH) and
   of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281.


5. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in
   patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized
   clinical trial. J Hypertens. 2013;31:2094.


6. Vongpatanasin W.  Resistant hypertension: a review of diagnosis and management. JAMA.
   2014;311:2216.


7. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and
   doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a
   randomised, double-blind, crossover trial. Lancet. 2015;386:2059.

21 Teaching Programmes